Core Viewpoint - The company has completed the commitment of fundraising investment for certain projects and plans to permanently supplement its working capital with the remaining funds, which is expected to enhance the efficiency of fund utilization and support its operational activities [1][6][7]. Fundraising Basic Situation - The company was approved to publicly issue 61,621,142 shares at a price of RMB 28.18 per share, raising a total of RMB 1,736,483,781.56, with the net amount after deducting underwriting fees and other expenses being RMB 1,736,483,781.56 [1][2]. Fundraising Investment Plan - The company has outlined its fundraising investment plan in accordance with its prospectus and subsequent announcements, detailing the allocation of funds to various projects, including new drug development and digital factory construction [2][3]. Fund Usage and Surplus Situation - As of August 29, 2025, the company has completed the committed investments for the "new drug development project for autoimmune and ophthalmic diseases" and the "innovation antibody drug industrialization and digital factory construction project," with other fundraising projects concluded [3][4]. Reasons for Fund Surplus - The surplus in fundraising is attributed to effective cost control and management during project execution, leading to lower investment costs. Additionally, the company has generated investment income from temporarily idle funds [4][5]. Surplus Fund Usage Plan - The company plans to permanently supplement its working capital with RMB 7,029.08 million of surplus funds, which will be used for daily operational activities to enhance cash flow and economic efficiency [5][6]. Approval Procedures - The board of directors and the supervisory board have approved the plan to use surplus funds, confirming that it aligns with the company's development strategy and does not harm the interests of shareholders [6][7].

Core Viewpoint - Sangfor Biopharmaceuticals (Shanghai) Co., Ltd. has completed the investment commitments for its antibody drug research projects and has decided to permanently supplement its working capital with the remaining funds from these projects [1][6]. Fundraising Overview - The company was approved to publicly issue 61,621,142 shares at a price of RMB 28.18 per share, raising a total of RMB 1,736,483,781.56, with a net amount of RMB 1,634,428,187.64 after deducting fees [1][2]. Investment Projects - The main projects funded include: - New drug research for autoimmune and ophthalmic disease antibodies - Industrialization of innovative antibody drugs and digital factory construction - The total investment for these projects is RMB 335,433.49 million, with RMB 318,275.95 million allocated to the new drug research project and RMB 163,442.82 million to the industrialization project [3][4]. Fund Usage and Surplus - As of August 29, 2025, the company has completed the investment commitments for the aforementioned projects, with a total of RMB 163,733.77 million utilized, resulting in a surplus of RMB 7,029.08 million [4][6]. - The surplus funds will be permanently supplemented into the company's working capital to enhance cash flow and economic efficiency [6]. Approval Process - The board of directors and the supervisory board approved the decision to use the surplus funds, stating it would improve fund utilization efficiency and align with the company's development strategy [6][7]. - The sponsor institution confirmed that the process followed necessary legal procedures and complied with relevant regulations, ensuring no adverse impact on the company's operations [7][8].

三生国健: 安永华明会计师事务所（特殊普通合 伙）对公司2024年度募集资金存放与使用情况鉴证 报告 三生国健药业（上海）股份有限公司 募集资金存放与实际使用情况鉴证报告 三生国健药业（上海）股份有限公司 目 录 页 次 一、 募集资金存放与实际使用情况鉴证报告 1-2 二、 三生国健药业（上海）股份有限公司 A member firm of Ernst & Young Global Limited 募集资金存放与实际使用情况鉴证报告（续） 安永华明（2025）专字第 70072706_A02号 募集资金存放与实际使用情况鉴证报告 安永华明（2025）专字第 70072706_A02号 三生国健药业（上海）股份有 | 限公司 | | | --- | --- | | | 三生国健药业（上海）股份有限公司董事会： | | | 我们接受委托，对后附的三生国健药业（上海）股份有限公司2024年度募集资金 | | 存放 | | | | 与实际使用情况的专项报告（"募集资金专项报告"）进行了鉴证。按照《上市公司 | | 监管 | | | | 指引第2号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所科创 | ...